[Selection of one of the TNF blockers; infliximab and etanercept].

Article Details

Citation

Copy to clipboard

Mimura T

[Selection of one of the TNF blockers; infliximab and etanercept].

Nihon Rinsho. 2007 Jul;65(7):1282-6.

PubMed ID

17642244 [ View in PubMed

]

Abstract

Infliximab and etanercept, both of which inhibit tumor necrosis factor (TNF), show almost an equal efficacy in reducing disease activity of rheumatoid arthritis and suppressing joints and bone destruction in the disease. Requiring a concomitant usage of methotrexate (MTX), infliximab, a chimeric antibody against TNF-alpha, blocks TNF-alpha and kills TNF-alpha -producing cells. Etanercept, on the other hands, is a soluble TNF receptor which blocks TNF-alpha as well as TNF-beta but does not affect cells producing TNF-alpha. MTX is not required on the etanercept administration because no neutralizing antibodies against etanercept are theoretically generated. The strategy selecting one of them for a patient should be based on the understanding differences and characteristics of the reagents.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Infliximab	Tumor necrosis factor	Protein	Humans	Yes	Inhibitor	Details